Sep. 17 at 11:43 AM
Goldman Sachs initiated coverage of
$TRDA at an Early-Stage Biotech rating. [
$SRPT $EWTX $PTCT SLDB
$RGNX PEPG RNA]
Goldman Sachs said:
We initiate coverage of Entrada Therapeutics (
$TRDA) with an Early-Stage Biotech (ESB) designation.
In our view,
$TRDA's proprietary Endosomal Escape Vehicle (EEV) platform is differentiated from other delivery peptide approaches, and as such, we see best-in-class potential driven by key properties including:
1) enhanced cellular uptake,
2) a wider therapeutic index, and most notably
3) a better safety profile.
Within the broader Duchenne muscular dystrophy (DMD) treatment paradigm, we continue to evaluate the positioning of gene therapies relative to exon-skipping therapeutics following recent safety events observed with
$SRPT's Elevidys.
With the barriers to entry for next generation DMD therapeutics lowered, we are cautiously positive on the efficacy/safety profile of
$TRDA's burgeoning clinical-stage portfolio and translation of data into the clinic.
